BiotechTube

SAGE-718

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Dec 14, 2022 → Jan 20, 2025

NCT ID
NCT05655520

About SAGE-718

SAGE-718 is a phase 3 stage product being developed by Supernus Pharmaceuticals for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05655520. Target conditions include Huntington's Disease.

What happened to similar drugs?

1 of 1 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (0) Active (0)
✅TetrabenazineLundbeckApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05655520Phase 3Terminated
NCT04602624Phase 2Completed
NCT04476017Phase 2Completed
NCT03787758Phase 1Completed

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
TetrabenazineLundbeckApproved
36
BN82451B + PlaceboIpsenPhase 2
24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25